Status:

RECRUITING

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

Lead Sponsor:

Sun Yat-sen University

Collaborating Sponsors:

JiangXi Province Tumor Hospital

Fujian Province Tumor Hospital

Conditions:

Nasopharyngeal Carcinoma

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine whether concurrent chemotherapy and IMRT is effective in the treatment of locally stage T3/T4 recurrent nasopharyngeal carcinoma patients compared with IMRT a...

Detailed Description

Locally T3/T4 recurrent nasopharyngeal carcinoma (NPC) may be salvaged by intensity modulated-radiotherapy (IMRT), but local control is not good enough and late toxicities is usually severe The aim of...

Eligibility Criteria

Inclusion

  • Pathologically or clinically confirmed rT3/T4 locally recurrent nasopharyngeal carcinoma;
  • No evidence of distant metastasis
  • More than 1 year from the end of the first course of radiotherapy
  • Male, or female not in the phase of lactating or pregnancy
  • ECOG 0-2
  • Aged 18-70 years old
  • WBC count ≥4×109/L, neutrophile granulocyte count≥1.5×109/L, PLT count ≥100×109/L, Hb ≥9g/L
  • Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of upper normal limits
  • Written informed consort signed

Exclusion

  • Only regionally recurrence
  • Evidence of distant metastasis
  • Prior invasive malignancy; noninvasive cancers (For example, carcinoma in situ of the bladder, oral cavity, or cervix are all permissible) are permitted
  • Severe, active co-morbidity
  • Prior anti-tumor treatment after diagnosis of local recurrence
  • MRI was not performed 3 months after the first course of radiotherapy
  • Abnormal function of heart, brain and lungs, etc
  • Lactation or pregnancy
  • Severe nasopharyngeal mucosal necrosis at the diagnosis of local recurrence

Key Trial Info

Start Date :

January 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

346 Patients enrolled

Trial Details

Trial ID

NCT04136886

Start Date

January 1 2020

End Date

December 1 2027

Last Update

October 23 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

WangHanYu

Guangzhou, Guangdong, China, 510060